Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 43,915 shares at $270.17 ($11.9M) on 2024-08-12, disclosed to the SEC on 2024-08-14.
Scheduled sale ($11.9M) by CSO & EVP, Head of Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $268.66 | 1,421 | $382K | 3.2% |
| 2 | $268.66 | 1,421 | $382K | 3.2% |
| 3 | $270.17 | 9,662 | $2.6M | 21.9% |
| 4 | $270.17 | 9,662 | $2.6M | 21.9% |
| 5 | $271.32 | 5,736 | $1.6M | 13.1% |
| 6 | $271.32 | 5,736 |
| $1.6M |
| 13.1% |
| 7 | $272.43 | 3,913 | $1.1M | 9.0% |
| 8 | $272.43 | 3,913 | $1.1M | 9.0% |
| 9 | $273.73 | 1,158 | $317K | 2.7% |
| 10 | $273.73 | 1,158 | $317K | 2.7% |
| 11 | $274.65 | 135 | $37K | 0.3% |
| Total | $270.98 avg | 43,915 | $11.9M | 100% |
| Filing → |
| ALNY | SELL | 2026-02-17 | $1.3M | — | Filing → |
| ALNY | SELL | 2026-01-14 | $1.4M | — | Filing → |
| ALNY | SELL | 2025-11-19 | $7.1M | — | Filing → |